Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stemirna mRNA COVID-19 Vaccine Booster Trial
NCT04944381Unknown
- Start
- Jul 2021
- Primary completion
- Aug 2021
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics, mRNA Therapeutics
01
Overview
Open-label trial of SW-BIC-213 in coronavirus disease 2019 (COVID-19) (2 arms). Primary endpoints: Geometric Mean Titer of Neutralizing Antibody at 28 days and Incidence of Solicited Adverse Events at 7 days. Status: unknown.
02
Drugs
SW-BIC-213
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04944381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04944381.